Sugi Predict

Sugi Predict / Compounds / SCHEMBL372008

SCHEMBL372008

SCHEMBL372008

CS(=O)(=O)OCC1CC2CN(C(=O)OCc3ccccc3)CC2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F13A1 P00488 3/20 0.48
▸ TGM2 P21980 3/20 0.48
▸ TGM1 P22735 3/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ CYP2C19 P33261 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ HTR2C P28335 1/20 0.43
▸ PDE4B Q07343 3/20 0.42
▸ MMP1 P03956 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ MMP9 P14780 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ GRIN2B Q13224 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096075 0.90 SMN1; SMN2 (0.50) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL3443323 0.84 SMN1; SMN2 (0.55) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL3444512 0.84 SMN1; SMN2 (0.55) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL3443325 0.84 SMN1; SMN2 (0.55) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL24136459 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL17633253 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL9873300 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL20983428 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL17633251 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL17633250 0.83 F13A1 (0.49) F13A1TGM2TGM1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
EP-1874759-A1 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2008-01-09 — — EP disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
WO-2006108059-A1 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2006-10-12 — — WO disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET F13A1 1544/4885TGM2 2638/4885TGM1 1716/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET F13A1 1544/4885TGM2 2638/4885TGM1 1716/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET F13A1 1544/4885TGM2 2638/4885TGM1 1716/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET F13A1 1544/4885TGM2 2638/4885TGM1 1716/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 F13A1 1693/4885TGM2 2706/4885TGM1 1458/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 F13A1 1693/4885TGM2 2706/4885TGM1 1458/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 F13A1 1693/4885TGM2 2706/4885TGM1 1458/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET F13A1 1544/4885TGM2 2638/4885TGM1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.